Federal Register Notice: FDA is seeking public comment on a proposed collection of information by the agency on a study, “Risk and Benefit Perception Scale Development.” The study is designed to test different ways of measuring consumers’ benefit and risk perceptions after exposure to direct-to-consumer prescription drug advertising. Comments should be submitted by 6/20. To view this notice, click here.
